10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study

BACKGROUND. Vascular endothelial growth factor (VEGF)-targeted agents are standard therapies for metastatic renal cell carcinoma (mRCC), associated with variable tumor shrinkage. Response Evaluation Criteria in Solid Tumors (RECIST) is of limited utility in this setting, and other imaging changes ar...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Krajewski, Katherine M., Franchetti, Yoko, Nishino, Mizuki, Fay, André P., Ramaiya, Nikhil, Van den Abbeele, Annick D., Choueiri, Toni K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2014
Konular:
Genitourinary Cancer: Renal, Bladder, and Testicular
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4012965/
https://ncbi.nlm.nih.gov/pubmed/24755461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0391
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller